A recent market study published by FMI on the pharmacovigilance market includes global industry analysis for 2016-2020 & opportunity assessment for 2021-2031, and delivers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historical and current growth parameters of the pharmacovigilance market, growth prospects of the market are obtained with maximum precision.
Pharmacovigilance Market: Taxonomy
Phase of Drug Development
- Preclinical Studies
- Phase I
- Phase II
- Phase III
- Phase IV
Type of Methods
- Spontaneous Reporting
- Intensified ADR Reporting
- Targeted Spontaneous Reporting
- Cohort Event Monitoring
- EHR Mining
Service Type Provider
- In-house Pharmacovigilance
- Contract Outsourcing
Geography
- North America (US and Canada)
- Europe (Germany, UK, France, Italy, Spain, Russia and Rest of Europe)
- Asia-Pacific (China, India, ASEAN, Japan and Rest of APAC)
- Latin America (Brazil, Mexico and Rest of LATAM)
- Middle East & Africa (GCC, South Africa and Rest of MEA)
Request a Sample of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1107
Report Chapters
Chapter 01 – Introduction
The report begins with a detailed description of the market, followed by a detailed research methodology, providing insights on the primary as well as secondary sources referred to during the course of the study. Furthermore, it also provides an overview of the market’s key segments.
Chapter 02 – Executive Summary
This section provides an executive summary of the pharmacovigilance market, which includes a summary of key findings and statistics of the market. It also includes the demand-side & supply-side trends about the pharmacovigilance market.
Chapter 03 – Pharmacovigilance Market Dynamics
This chapter begins by providing a detailed taxonomy in the form of segments. This chapter explains key macro-economic factors that are expected to influence the growth of the pharmacovigilance market over the forecast period. Along with the macroeconomic factors, this section also highlights the value chain and forecast factors for the pharmacovigilance market. Moreover, in-depth information about the market dynamics and their impact analysis on the market have been provided.
Chapter 04 – Global Pharmacovigilance Market Analysis by Phase of Drug Development
Based on phase of drug development, the pharmacovigilance market is segmented into preclinical studies, phase I, phase II, phase III and phase IV. In this chapter, readers can find information about the key trends and developments in the pharmacovigilance market and market attractiveness analysis based on phase of drug development.
Chapter 05 – Global Pharmacovigilance Market Analysis by Type of Methods
Based on type of methods, the pharmacovigilance market is segmented into spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event reporting and EHR mining. In this chapter, readers can find information about the key trends and developments in the pharmacovigilance market and market attractiveness analysis based on type of methods.
Chapter 06 – Global Pharmacovigilance Market Analysis by Service Type Provider
Based on service type provider, the pharmacovigilance market is segmented into in-house pharmacovigilance and contract outsourcing. In this chapter, readers can find information about the key trends and developments in the pharmacovigilance market and market attractiveness analysis based on service type provider.
Chapter 07 – Global Pharmacovigilance Market Analysis 2016-2020 & Opportunity Assessment 2021-2031, by Geography
This chapter explains how the pharmacovigilance market will grow across several geographic regions such as North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Get Full Report Buy Now @ https://www.futuremarketinsights.com/checkout/1107
Chapter 08 – North America Pharmacovigilance Market Analysis 2016-2020 & Opportunity Assessment 2021-2031
This chapter includes a detailed analysis of the growth of the North America pharmacovigilance market, along with a country-wise assessment that includes the U.S. and Canada. Readers can also find the pricing analysis, regional trends, and market growth based on end use and countries in North America.
Chapter 09 – Latin America Pharmacovigilance Market Analysis 2016-2020 & Opportunity Assessment 2021-2031
This chapter provides the growth scenario of the pharmacovigilance market in Latin American countries such as Brazil, Mexico and the Rest of Latin America. Along with this, an assessment of the market across target segments has been provided.
Chapter 10 – Europe Pharmacovigilance Market Analysis 2016-2020 & Opportunity Assessment 2021-2031
Important growth prospects of the pharmacovigilance market based on its end use in several countries such as Germany, U.K., France, Spain, Italy, Russia and Rest of Europe are included in this chapter.
Chapter 11 – Asia Pacific Pharmacovigilance Market Analysis 2016-2020 & Opportunity Assessment 2021-2031
Important growth prospects of the pharmacovigilance market based on its end use in several countries such as China, India, ASEAN, Japan and Rest of Asia-Pacific are included in this chapter.
Chapter 12 – Middle East & Africa Pharmacovigilance Market Analysis 2016-2020 & Opportunity Assessment 2021-2031
This chapter highlights the growth of the pharmacovigilance market in Middle East & Africa by focusing on GCC countries, South Africa and Rest of MEA. This section also helps readers understand the key factors that are responsible for the growth of the pharmacovigilance market in Middle East and Africa.
Chapter 13 – Global Pharmacovigilance Market Recommendations
In this chapter, reader can glean information about recommendations concerning key market strategies implementation. This section incorporates an in-depth discussion on strategic partnerships and collaborations with CROs and life sciences BPOs, optimization of drug safety through Hub and Spoke model, developing operation activities for better outcomes and regional expansion.
Request for Report Ask A Question @ https://www.futuremarketinsights.com/ask-question/rep-gb-1107
Chapter 14 – Global Pharmacovigilance Market Company Profiles
In this chapter, readers can find a comprehensive list of all the prominent stakeholders in the pharmacovigilance market, along with detailed information about each company, which includes company overview, revenue shares, strategic overview, and recent company developments.
Some of the market players featured in the report are Accenture Plc., Bristol-Myers Squibb, Clinquest Group B.V., Cognizant Technology Solutions, Covance Inc, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., ICON Plc, iGATE Corporation, iMED Global Corporation, inVentiv Health Inc., Novartis AG, PAREXEL International Corporation, Pfizer Inc., Pharmaceutical Product Development LLC. (PPD), PRA Health Sciences Inc., Quintiles Transnational Holdings Inc., Sanofi SA, Synowledge LLC and Wipro Ltd. among others.
Network analytics provide network intelligence solutions, and professional and managed services.
The availability of various service options is likely to gain traction for the global market.
In addition, the optimization of networks enabled by network analytics helps in the retention of customers and expand the consumer base by providing a better experience.
An increase in the adoption rate of network analytics solutions is observed due to the proactive need to overcome the threat of misuse of critical data of organizations.
The market in Europe is expected to show considerable growth.
The Asia Pacific market of network analytics market is expected to show healthy growth during the forecast years.
According to the latest market report published by Research Report Insights titled ‘Global Triple-Negative Breast Cancer Treatment Market: Global Industry Analysis, Size, Sales and Forecast By 2026,’ the global triple-negative breast cancer treatment market is projected to reach US$ 727 Mn by the end of 2026and grow at a CAGR of 4.9% during the forecast period.Global Triple-Negative Breast Cancer TreatmentMarket: DynamicsTriple-negative breast cancer is a type of cancer that does not have receptors for the hormones oestrogen and progesterone or the protein HER2.
Triple-negative breast cancer is arare type of cancer.
About 10–20% of breast cancers are found to be triple negative.Request For Report Sample: https://www.researchreportinsights.com/report/sample/110115008/Triple-Negative-Breast-Cancer-Treatment-MarketIncreasing per capita healthcare expenditure and shift towards value-basedcare are the major factorsexpected todrive the growth of themarket fortriple-negative breast cancer treatment over the forecast period.Furthermore, increasing number of research and development activities in therapeutic areas such as cancer and adoption of new treatments for breast cancer are the other factors expected to spur the growth of the market for triple-negative breast cancer over the forecast period.Many new treatments for the triple-negative breast cancer are under study, among which are drug therapies.
Introduction of new drugs and treatments will further improve the diagnosis and treatment for triple-negative breast cancer.Likewise, emerging technologies such as nanotechnology for managing triple-negative breast cancer are alsoexpected to drive the growth of the market fortriple-negative breast cancer treatment.The progress in the development of drugs that use novel approaches to kill cancer and inhibit the growth of cancer cells through different therapies in partnership with the other manufactures is also expected to boost the growth of the triple-negative breast cancer market.However, regulations set up by the FDA and European Union for the approval of cancer drugs are expected to hamperthe growth of the triple-negative breast cancer treatment market.Global Triple-Negative Breast Cancer TreatmentMarket:ForecastThe global triple-negative breast cancer treatment marketis segmented on the basis of drug type, and distribution channel.
On the basis of drug type, the global triple-negative breast cancer treatment market is segmented into doxorubicin, cyclophosphamide, paclitaxel, docetaxel, carboplatin/cisplatin and others.The paclitaxelis expected to be the leading segment in the global triple-negative breast cancer treatment market over the forecast period.The paclitaxel andothers segmentscollectively accounted atotal value share of 73% of the global triple-negative breast cancer treatment marketin 2017.
The docetaxelsegment is estimated to have incremental opportunity of US$ 27 Mn between 2016 and 2026.The paclitaxelsegment is expected to hold high share in the globaltriple-negative breast cancer treatment marketastreatment with paclitaxel shows promising results in the overall treatment of triple-negative breast cancer as well asbetter tolerability than the conventional taxanes in metastatic breast cancer.Request Report Discount: https://www.researchreportinsights.com/report/discount/110115008/Triple-Negative-Breast-Cancer-Treatment-MarketGeographically, the globaltriple-negative breast cancer treatmentmarket has been segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
ReportCrux Market Research has published a new report titled "Biopharma Market by Product(Monoclonal Antibodies [Anti Cancer Monoclonal Antibodies, Anti Inflammatory Monoclonal Antibodies, and Other Monoclonal Antibodies], Purified Proteins [Leukemia Inhibitory Factor (LIF), P53 Protein, P38 Protein, and Other Purified Proteins], Recombinant Proteins [Serum Albumin, Amyloid Protein, Defensin, and Transferrin],Vaccines [Recombinant Vaccines, Conventional Vaccines, and Recombinant Enzymes], Recombinant Growth Factors [Erythropoietin, and Granulocyte Colony Stimulating Factors], Recombinant Hormones [Recombinant Human Growth Hormones, Recombinant Insulin, and Other Recombinant Hormones], and Other Product Types); by Therapeutic Application (Oncology, Inflammatory and Infectious Diseases, Neurological Diseases, Infectious Diseases, Cardiovascular Diseases, Metabolic Disorders, Hormonal Disorders, and Other Diseases).Biopharmaceuticals Market SizeBiopharma Market is estimated to grow from USD 244.1 Billion in 2019 to USD 546.6 Billion by 2027, at a CAGR of 10.6% during 2020-2027Biopharmaceuticals are produced by living organisms, such as microorganisms and animal cells, and have a high therapeutic value.
Most biopharmaceuticals are life-form pharmaceutical products, genetically modified from plants and animals and are classified as transgenic organisms, and this process is used to generate biopharmaceuticals.These massive and complex molecular drugs are often referred to as biologics or biotech drugs.
Recombinant human insulin was one of the first substances to be licensed for medical purposes, and there are currently almost 300 biopharmaceutical drugs that have been licensed and are available on the market.The global demand for biopharmaceuticals is driven by a number of factors like increase in the elderly population, an increase in the prevalence of chronic diseases like cancer and diabetes, and an increase in the global acceptance of biopharmaceuticals.
In addition, an increase in strategic partnerships between biopharmaceutical companies is also expected to complement the growth of the biopharmaceuticals industry.Furthermore, clearance for newer biopharmaceutical products and continuous R is also expected to improve this market positively.
However, the high costs of these medications are one of the main constraints on this industry and, in order to make them economically viable, the cost needs to be reduced greatly.Segmentation AnalysisThe global market for the biopharma is segmented into product, therapeutic area, application, and region.By ProductRecombinant growth factorsMonoclonal antibodiesRecombinant proteinsVaccinesPurified proteinsRecombinant hormonesOtherMonoclonal:28%By Therapeutic Applicationoncologyinflammatory and infectious diseasesneurological diseasesinfectious diseasescardiovascular diseasesmetabolic disordershormonal disordersotherOncology:25%By RegionNorth AmericaLatin AmericaEuropeAsia-PacificMiddle-East & AfricaNorth America:37%By ProductBased on product, the market is for biopharma is segmented into recombinant growth factors, monoclonal antibodies, recombinant proteins, vaccines, purified proteins, recombinant hormones, and other product types.
Contrary, the recombinant proteins segment is expected to show rapid growth over the forecast period.By Therapeutic ApplicationBased on therapeutic application, the market is categorized into oncology, inflammatory and infectious diseases, neurological diseases, infectious diseases, cardiovascular diseases, metabolic disorders, hormonal disorders, and other diseases.
The rising adoption of blockchain in the energy industry and growing safety concerns related to automated grids are driving the demand for the market.The global Blockchain in Energy Market is forecasted to be worth USD 8,761.4 Million by 2027, according to a current analysis by Emergen Research.
During the forecasted timeline, the global blockchain in the energy market is expected to rise substantially, owing to the rising adoption of blockchain in the energy industry.
The growing safety concerns related to automated grids is anticipated to further propel the market growth in the forecast period.
Besides, the rising internet of things technology penetration is likely to drive the market growth shortly.The research offers a bird’s eye view of the current market scenario regarding the operations of the leading companies in the Blockchain in Energy market.
The report presents an extensive analysis of the leading players with regards to their business portfolio, product portfolio, market share and size, global reach and position, revenue share, gross profit margins, and production and manufacturing capacity.Download the report description @ https://www.emergenresearch.com/request-sample/350 The power industry is expected to dominate the market with a CAGR of 56.2% over the forecasted period.
It's mainly due to blockchain technologies' ability to manage decentralized sources of energy and a holistic view of energy consumption through tracking.Radical Highlights of the Blockchain in Energy Market Report:Study of the latest product launches and technological advancements to help the readers in formulating investment strategiesFocus on market scenario, dynamics, and trends to be expected in the coming yearsAdvanced analytical tools such as Porter’s Five Forces analysis, SWOT analysis, feasibility analysis, and investment return analysisThorough regional analysis to offer insights into production and consumption patterns, supply and demand ratio, market size, revenue contrition, and the presence of prominent playersCompetitive landscape benchmarking with a focus on business profiles, product portfolio, business strategies such as M activities, revenue, market positions, market share, global position, and financial standingKey participants include Infosys Limited, SAP SE, Oracle Corporation, Accenture plc, WePower UAB, IBM Corporation, Microsoft Corporation, Deloitte Touche Tohmatsu Limited, LO3 Energy, Inc., and BigchainDB GmbH, among others.
Market HighlightsThe global Location of Things market, according to the analysis of Market Research Future (MRFR), is slated to acquire a significant market valuation of up to USD 38 Billion by 2023, at a substantial 35% CAGR over the review period of2017 and 2023.
Drivers and RestraintsThe major influential factors that are driving the growth of the location of things market comprise of the increasing importance of spatial data, the location-based democratization of geospatial data for IoT applications, and increase in the adoption of location-based applications across various verticals.
The increasing adoption of technological advancements, rising expenditure towards research and development projects for the development of new technologies, and the increasing industrialization across the globe is expected to drive the global Location of Things market over the assessment period.Get a Free Sample @https://www.marketresearchfuture.com/sample_request/2965Segmentation:The global location of things market has been segmented on the basis of application type, location type, vertical, and regional.Based on the location type, the market has been bifurcated into indoor and outdoor.
It is used to study and evaluate data or the image produced.
The incorporation of GIS and interactive mapping of technology offers comprehensive solutions for workforce management.
The retail segment is anticipated to show significant growth during the forecast period.Retail is all about integrating advanced technologies with the existing infrastructure.
